Drugs / Navuliumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05202561 | Mar 2022 → Jan 2023 | neoplasm | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Navuliumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05202561 ↗ |
| Action | Inhibit | “PD-1 inhibitor” NCT05202561 ↗ |
| Route | Intravenous | “3 mg/kg, intravenous injection every 2 weeks” NCT05202561 ↗ |